Immucell Corp

Name: Immucell Corp standardized financial statements, quarterly
Creator: Listed

ICCCNasdaqCIK 811641HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$7.2m, Q2 FY2026

Operating income$1.9m, Q2 FY2026

Net income$1.8m, Q2 FY2026

Immucell Corp, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	5.4	0.0	7.3	5.5	6.0	7.8	8.1	6.4	5.5	7.6	10.4	7.2
Cost of revenue	$m	4.1	0.0	5.0	4.2	4.4	4.9	4.7	3.6	3.1	4.7	5.7	4.7
Gross profit	$m	1.3	0.0	2.3	1.2	1.6	2.8	3.4	2.8	2.4	2.9	4.7	2.4
Research and development	$m	1.1	0.0	1.3	1.0	0.8	0.8	0.8	0.8	0.7	0.8	0.3	0.1
Operating income	$m	(1.2)	0.0	(0.3)	(1.4)	(0.6)	0.6	1.1	0.6	0.0	(0.1)	2.0	1.9
Interest expense	$m	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Income tax	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$m	(0.9)	(1.1)	(0.4)	(1.5)	(0.7)	0.5	1.4	0.5	(0.1)	(2.8)	1.9	1.8
Diluted EPS	$ per share	(0.12)	not reported	(0.06)	(0.20)	(0.09)	not reported	0.16	0.06	(0.02)	not reported	0.21	0.20
Basic EPS	$ per share	(0.12)	not reported	(0.06)	(0.20)	(0.09)	not reported	0.16	0.06	(0.02)	not reported	0.21	0.20

Balance sheet

Cash and equivalents$8.9m, Q2 FY2026

Long-term debt$6.8m, Q2 FY2026

Shareholders' equity$31.4m, Q2 FY2026

Immucell Corp, balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	2.0	1.0	1.0	1.3	not reported	3.8	not reported	not reported	3.9	3.8	6.8	8.9
Current assets	$m	12.0	11.5	11.3	10.8	13.9	15.0	15.9	17.1	16.8	16.9	18.9	21.1
Total assets	$m	44.5	43.8	43.1	41.9	44.4	45.1	45.6	42.5	45.7	42.5	44.1	46.6
Current liabilities	$m	3.3	4.2	4.2	4.6	4.5	4.4	3.9	4.4	4.0	4.0	3.9	4.4
Total liabilities	$m	18.5	18.8	18.4	18.4	18.0	17.6	16.6	16.9	15.9	15.5	15.0	15.3
Long-term debt	$m	12.3	not reported	not reported	not reported	not reported	9.0	10.2	8.3	7.9	7.5	7.1	6.8
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	1.5	not reported	1.5	1.6	1.6	1.6	1.5
Short-term borrowings	$m	not reported	10.4	10.1	9.9	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	26.0	25.0	24.6	23.5	26.4	27.5	29.0	29.9	29.8	27.1	29.1	31.4

Cash flow

Operating cash flow$3.0m, Q2 FY2026

Capital expenditure$733.9k, Q2 FY2026

Immucell Corp, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(508)	(723)	419	582	(639)	(3.1)	1,574	1,601	(1,183)	483	3,573	3,019
Capital expenditure	$k	421	81.3	70.4	111	88.4	196	329	155	594	172	177	734

Diluted shares (weighted)9.19m, Q2 FY2026

Immucell Corp, shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	7,747	7,747	7,747	7,747	7,751	7,810	8,164	8,981	9,031	9,046	9,046	9,189

Shares outstanding: 9.08m at Jul 31, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. Listed shows no prices and gives no investment advice.